Abstract:Human tumor necrosis factor alpha (hTNF-alpha) is one of the most important inflammatory cytokines that acts as a mediator in inflammatory and immune response and plays a key role in host defense against infection. The over expression of hTNF-alpha is associated with serious consequences, such as shock, hypotension, thrombus, septicemia and even death. It has been implicated in many autoimmune and inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, chronic heart failure and septic shock. Inhibiting the bio-activity of hTNF-alpha is one of the strategy for the treatment of these diseases. Compared with traditional recombinant protein drugs, small molecule drugs have many advantages, such as high affinity, low immunogenecity and low cost. Systematic evolution of ligands by exponential enrichment (SELEX) is a powerful method for the selection of oligonucleotides that bind with high affinity and specificity to target proteins. Such oligonucleotides are called aptamers, and are potential therapeutics for blocking the activity of pathologically relevant proteins. To obtain oligonucleotide aptamers specifically binding to TNF, a 40nt random DNA combinatorial library flanked by 31nt fixed sequences was chemically synthesized. The random library was amplified with PCR and subjected to selection by SELEX protocol against hTNFalpha. After incubation of the library with hTNFalpha, the mixture was blotted onto Immobilon-NC transfer membrane. The no-specific binding was washed away and the hTNFa binding aptamers were eluted and detached from the target protein. The eluted oligo nucleotides were amplified with PCR and served as the DNA library for the next round selection. After 12 rounds of such selection, the selected aptamers were cloned to pGEM-T vector. Positive clones were identified by restriction enzyme digestion and DNA sequencing. Oligo DNA were synthesized according to the sequence data and tested for their activities. Binding activity of the aptamers to hTNFalpha were detected by ELISA and dot blot with biotin-streptavidin-horseradish peroxidase system. Mouse L929 cells were used to test the anti-hTNFa activity of the DNA aptamers. The aptamers were incubated with hTNFalpha and added to the L929 cells. The results were read under microscope and with MTT staining. It was shown that these DNA aptamers bound to hTNFalpha with high affinity, and can inhibit the cytotoxicity of hTNFalpha on cell culture. The affinity of these aptamers are different and may related to their structure. These ssDNA aptamers are potential for the treatment and diagnosis of hTNFalpha related diseases.

Preparation and Characterization of a Fully Human Monoclonal Antibody Specific for Human Tumor Necrosis Factor Alpha

[Preparation and Characterization of Monoclonal Antibody Against Human Telomeric Repeat Binding Factor 1].

Preparation and identification of transmembrane TNF-α(TM-TNF-α)specific monoclonal antibody

Engineering and Characterization of a Humanized Antibody Targeting TNF-α and RANKL.

Characterization of a novel anti-human TNF-α murine monoclonal antibody with high binding affinity and neutralizing activity

Reconstruction and Analysis of A Human Small Molecular Antibody to Tumor Necrosis Factor Alpha

Safety evaluation and pharmacokinetics of a novel human tumor necrosis factor-alpha exhibited a higher antitumor activity and a lower systemic toxicity.

Purification and Characterization of Rgd Tumor-Homing Peptide Conjugated Human Tumor Necrosis Factor Alpha Over-Expressed in Escherichia Coli

[Screening and Characterization of DNA Aptamers with Htnf-Alpha Binding and Neutralizing Activity].

A Novel Domain Antibody Rationally Designed Against TNF-α Using Variable Region of Human Heavy Chain Antibody As Scaffolds to Display Antagonistic Peptides

Interaction Between an Anti-Human Tumor Necrosis Factor-Alpha Single Chain Antibody and Its Ligand

Production of Bioactive, SUMO-modified, and Native-Like TNF-α of the Rhesus Monkey, Macaca Mulatta , in Escherichia Coli

[Development of an Anti-Rtnf-alpha Chimeric Antibody].

The Protective Antibodies Induced by a Novel Epitope of Human TNF-α Could Suppress the Development of Collagen-Induced Arthritis

Preparation and Characterization of Monoclonal Antibodies Against Human Tenascin-C

Humanization of an Anti-Human Tnf-Alpha Antibody by Variable Region Resurfacing with the Aid of Molecular Modeling

A Tumor Necrosis Factor (TNF) Receptor-Igg Heavy Chain Chimeric Protein As a Bivalent Antagonist of TNF Activity.

Expression and Purification of Recombinant Human Tumor Necrosis Factor α in Escherichia Coli

Targeting TNF-α with a tetravalent mini-antibody TNF-TeAb

Purification and Biologic Characterization of Soluble Tumor Necrosis Factor Receptor

Preparation and Characterization of a Functional Monoclonal Antibody Against Human Tumor Necrosis Factor and B Lymphocyte Stimulator